Evaxion A/S (EVAX): Financial results for Q3 2026
Evaxion A/S (EVAX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Evaxion announces strategy and business update and third quarter 2026 financial results COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunolog
How this was made
The 30-second read
Why it matters
This filing is a combined earnings release and strategy update. It highlights new EVX-01 three-year follow-up data, outlines near-term EVX-04 development steps toward a Phase 1 application, and extends cash runway through ATM equity sales, which together can influence valuation through both clinical probability and financing-risk expectations.
Market read
Traders can reassess EVAX’s near-term risk profile using the disclosed EVX-01 follow-up metrics and the stated cash runway extension, while monitoring dilution and upcoming conference catalysts.
What to watch
The article notes organizational adjustments and partnership dependence for infectious disease programs, which could shift burn rate and execution priorities even if the headline clinical data is strong.
Evaxion reports Q3 2026 net loss of $3.5 million with no revenue, refocuses strategy on immuno-oncology and extends cash runway towards end of 2027
The filing reports no revenue in Q3 2026 against $7,492 thousand in Q3 2025, and a net loss of $(3,541) thousand against a net profit of $4,618 thousand a year earlier. Operating costs fell year over year, the company describes the result as in line with its expectations, and it states that its cash runway was extended towards the end of 2027 through ATM sales. The filing gives no guidance figures.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, Q3 2026other | - | – | – |
| Revenue, nine months 2026other | - | – | – |
| Research and development expenses, Q3 2026other | −$2.31M | – | – |
| Research and development expenses, nine months 2026other | −$6.94M | – | – |
| General and administrative expenses, Q3 2026other | −$1.36M | – | – |
| General and administrative expenses, nine months 2026other | −$4.39M | – | – |
| Operating profit/(loss), Q3 2026other | −$3.67M | – | – |
| Operating profit/(loss), nine months 2026other | −$11.34M | – | – |
| Finance income, Q3 2026other | $152K | – | – |
| Finance income, nine months 2026other | $557K | – | – |
| Finance expenses, Q3 2026other | −$212K | – | – |
| Finance expenses, nine months 2026other | −$730K | – | – |
| Net profit/(loss) before tax, Q3 2026other | −$3.73M | – | – |
| Net profit/(loss) before tax, nine months 2026other | −$11.51M | – | – |
| Income tax benefit, Q3 2026other | $191K | – | – |
| Income tax benefit, nine months 2026other | $611K | – | – |
| Net profit/(loss) for the period, Q3 2026other | −$3.54M | – | – |
| Net profit/(loss) for the period, nine months 2026other | −$10.90M | – | – |
| Loss per share, basic and diluted, Q3 2026other | (0.01) per share | – | – |
| Loss per share, basic and diluted, nine months 2026other | (0.03) per share | – | – |
| Cash and cash equivalents, September 30, 2026other | $13.3 million (USD 13,274 thousand in the balance sheet table) | – | – |
| Total assets, September 30, 2026other | $18.66M | – | – |
| Total equity, September 30, 2026other | $8.1 million (USD 8,143 thousand in the balance sheet table) | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- Through utilization of its At-The-Market (ATM) equity program, the company sold Evaxion shares for gross proceeds of $2.2 million, which the company says improved its cash at hand and equity and extended its cash runway towards the end of 2027.
- The company states it is not conducting a capital raise. It filed an amendment to a Form F-1 registration statement relating solely to possible resale by the European Investment Bank (EIB) of shares issuable on exercise of warrants issued under the 2025 debt settlement agreement.
What drove it
- The company states that no revenue was recorded in Q3 2026, whereas Q3 2025 included revenue from out-licensing EVX-B3 to MSD.
- According to the company, the reduction in costs compared with last year relates primarily to lower personnel expenses and capital market costs.
- The company states that the R&D reduction compared with Q3 2025 is mainly due to reduced headcount.
- The company states that G&A has lower capital market costs, compensated by higher business development costs.
- The company states that net financial expense of $0.1 million in Q3 2026 reflects normalized financial income and expenses, and that Q3 2025 was impacted by financial income from the EIB debt settlement agreement and financial expenses from a significantly higher derivative liability.
- The company describes the Q3 2026 financial results as in line with expectations. The filing does not state what those expectations were.
- The company states that the strategy refocus is intended to prioritize immuno-oncology assets, with infectious disease work to be conducted only if funded by external partners.
Concerns
- No revenue was recorded in Q3 2026 and the nine-month 2026 revenue line also shows no revenue, compared with $7,492 thousand in Q3 2025 and $7,528 thousand in the nine months 2025.
- The company reports a net loss of $(3,541) thousand in Q3 2026 and $(10,899) thousand for the nine months 2026, compared with net profit in Q3 2025 and a nine-month net loss of $(1,789) thousand.
- Total equity fell to $8,143 thousand from $17,039 thousand at December 31, 2025, and total assets fell to $18,665 thousand from $28,408 thousand over the same period.
- The company's cash runway is stated as extended towards the end of 2027, and the filing does not give a longer runway figure.
- The filing states that future work on infectious disease programs will only be conducted if funded by external partners, and that autoimmune work is limited to concept validation for potential partnerships.
What to watch
- Filing of the EVX-04 phase 1 trial application, which the company says is on track before the end of 2026.
- Presentation of new EVX-04 target validation data at the ASH Annual Meeting, New Orleans, December 12-15, 2026.
- Outcome of the business development discussions the company describes as ongoing, including partnerships for EVX-01 and the preclinical infectious disease assets.
- Further ATM equity sales and their effect on the cash runway, which the company states extends towards the end of 2027.
- Whether operating costs continue to be lower than the prior year, given the company's description of headcount reduction and lower capital market costs.
- Progress on the EVX-04 off-the-shelf vaccine, described by the company as its last milestone for the year.
Balance sheet and cash flow
- Cash and cash equivalents: $13,274 thousand at September 30, 2026, compared with $23,234 thousand at December 31, 2025 and $14.0 million at June 30, 2026 (per the text).
- Total assets: $18,665 thousand at September 30, 2026, compared with $28,408 thousand at December 31, 2025.
- Total liabilities: $10,523 thousand at September 30, 2026, compared with $11,369 thousand at December 31, 2025.
- Total equity: $8,143 thousand at September 30, 2026, compared with $17,039 thousand at December 31, 2025. The company attributes the decline to the net loss of the first nine months of 2026, partly offset by the proceeds from ATM sales.
- Share capital: $17,129 thousand at September 30, 2026, compared with $15,791 thousand at December 31, 2025.
- Accumulated deficit: $(139,288) thousand at September 30, 2026, compared with $(126,244) thousand at December 31, 2025.
- No operating cash flow, investing cash flow or free cash flow figures are printed in the filing.
Analysis
Evaxion reported a Q3 2026 net loss of $(3,541) thousand, or $3.5 million, against a net profit of $4,618 thousand in Q3 2025 and a net loss of $3.7 million in Q2 2026 as stated in the text. The company recorded no revenue in the quarter, compared with $7,492 thousand in Q3 2025, which the filing ties to the out-licensing of EVX-B3 to MSD in that period. Operating loss was $(3,673) thousand, against an operating profit of $3,022 thousand a year earlier. R&D expense was $(2,312) thousand and G&A expense was $(1,361) thousand, each lower than in Q3 2025 at $(3,092) thousand and $(1,377) thousand respectively. The company attributes the R&D decline mainly to reduced headcount.
Below the operating line, the company describes financial results as normalized. Finance income was $152 thousand and finance expenses were $(212) thousand, against $2,690 thousand and $(1,360) thousand in Q3 2025, a year that included financial income from the EIB debt settlement and expenses from a higher derivative liability. The income tax benefit was $191 thousand. The nine-month figures show a larger loss than the prior year on an operating basis, with an operating loss of $(11,338) thousand against $(5,182) thousand, while G&A and R&D for the nine months were lower than in 2025.
The balance sheet shows cash and cash equivalents of $13,274 thousand at September 30, 2026, down from $23,234 thousand at December 31, 2025 and $14.0 million at June 30, 2026. Total equity fell to $8,143 thousand from $17,039 thousand at December 31, 2025. The company says the decline reflects the nine-month net loss, partly offset by ATM proceeds, and that the ATM program generated gross proceeds of $2.2 million. The company states that its cash runway has been extended towards the end of 2027. The filing does not print operating or free cash flow figures for the period.
The strategy update is the main change in the filing. The company is refocusing on immuno-oncology, with EVX-04 and EVX-05 moved toward clinical development, EVX-01 expansion through partnerships, and infectious disease and autoimmune work largely dependent on external partners or concept validation. The company reports 89% vaccine target precision and three-year clinical outcome data for EVX-01 presented at ESMO 2026. The organizational adjustments that follow the refocus are referred to in the filing but not quantified.
Management, verbatim
We are refocusing our strategy on the unique capabilities of AI-Immunology™ in discovery and design of novel cancer vaccines.
Helen Tayton-Martin, CEO
we are maintaining strong operational momentum on all of our milestones for the year, tracking towards achieving the last one with the EVX-04 off-the-shelf vaccine clinical trial submission, as we re-focus our efforts towards immuno-oncology
Helen Tayton-Martin, CEO
Not in the filing
stated, not guessed- No forward guidance figures are printed in the filing.
- The accounting framework (IFRS, US GAAP or other) is not printed in the statements; basis is therefore recorded as 'other'.
- Q2 2026 R&D expense figure is not printed; the text says only that it was aligned with Q2 2026.
- Q2 2026 G&A expense figure is not printed; the text says only that it was level with Q2 2026.
- Q2 2026 operating loss, finance income, finance expenses, tax benefit and loss per share are not printed.
- Year-over-year and quarter-over-quarter percentage changes are not printed for any line item.
- Q3 2026 revenue and nine-month revenue prior-quarter comparisons are not printed.
- Cash flow statement figures (operating, investing and financing cash flow) are not printed.
- Balance sheet figures at June 30, 2026 other than cash are not printed.
- Size of the organizational adjustments and any restructuring costs are not quantified in the filing.
- The cash runway is described only as extending towards the end of 2027; no cash runway figure in months or a specific date is printed.
- Expectations against which the results are described as 'in line' are not specified in the filing.
- Dollar figures from the text ($13.3 million, $14.0 million, $3.5 million, $3.7 million, $2.2 million, $8.1 million, $17.0 million) are rounded in the text; the thousand-dollar figures are taken from the statement tables.
- The previous outlook covered the second half of 2027 and the period reported here is Q3 2026, so there is no matching guidance to compare.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Evaxion is a clinical-stage TechBio company using its AI-Immunology platform for personalized cancer vaccines (EVX-01) and off-the-shelf candidates (EVX-04/EVX-05), with additional infectious disease and autoimmune concepts.
Ticker impact
Evaxion reports Q3 2026 financial results and a refocused immuno-oncology strategy, including Phase 2 EVX-01 three-year data and EVX-04 clinical filing plans.
Likely modest upward bias as investors weigh strengthened EVX-01 validation and longer runway against dilution risk from the ATM program.
The article discloses specific EVX-01 three-year follow-up metrics (target precision and sustained responses) plus cash runway extension via ATM proceeds, but it does not provide revenue guidance or a quantified balance-sheet change beyond the stated gross proceeds.
Market effects
Adds incremental validation for AI-driven personalized and off-the-shelf cancer vaccine platforms, potentially supportive for sentiment toward similar clinical-stage immunotherapy developers.
Limited direct regional spillover beyond US-listed biotech sentiment.
Primarily US biotech investor focus due to NASDAQ listing and US conference milestones (ASH).
Counterpoint
The strategy refocus and cash runway extension may still imply continued dilution, and the EVX-04 timeline depends on successful IND-enabling work and regulatory acceptance.
Key entities
- companyEvaxion A/S
Clinical-stage immunotherapy company reporting Q3 2026 results and refocusing R&D toward immuno-oncology using AI-Immunology.
- pipeline_assetEVX-01
Personalized cancer vaccine in Phase 2, with reported three-year follow-up data and biomarker updates.
- pipeline_assetEVX-04
Off-the-shelf AML vaccine candidate targeting ERV antigens, with plans to file for a Phase 1 trial before year-end.
- financing_mechanismAt-The-Market (ATM) equity program
Used to extend cash runway, generating $2.2 million gross proceeds in the period described.
